Identification

Name
Methocarbamol
Accession Number
DB00423  (APRD01102)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

Structure
Thumb
Synonyms
  • (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
  • Delaxin
  • Methocarbamol
  • Méthocarbamol
  • Methocarbamolum
  • Metocarbamol
  • Metocarbamolo
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methocarbamol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousUnivet Pharmaceuticals Ltd.1988-12-31Not applicableCanada
Methocarbamol OmegaLiquid100 mgIntramuscular; IntravenousOmega Laboratories Ltd2003-07-28Not applicableCanada
Robaximol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousMontreal Veterinary Products Inc.1989-12-31Not applicableCanada
RobaxinTablet500 mg/1OralRemedy Repack2012-08-162016-10-13Us
RobaxinTablet, film coated500 mg/1OralEndo Pharmaceuticals2012-05-15Not applicableUs
RobaxinInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2017-10-17Not applicableUs
RobaxinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.2003-01-202016-12-21Us
RobaxinTablet, film coated750 mg/1OralStat Rx USA2003-01-202018-02-08Us
RobaxinTablet, film coated750 mg/1OralEndo Pharmaceuticals2011-08-18Not applicableUs
RobaxinInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1959-06-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethocarbamolTablet750 mg/1OralDispensing Solutions, Inc.2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralH.J. Harkins Company1987-11-01Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralClinical Solutions Wholsesale2017-07-06Not applicableUs
MethocarbamolTablet750 mg/1OralPreferreed Pharmaceuticals Inc.2014-11-25Not applicableUs
MethocarbamolTablet750 mg/1OralRemedy Repack2013-04-022016-03-12Us
MethocarbamolTablet, film coated750 mg/1OralVirtus Pharmaceuticals2015-07-13Not applicableUs
MethocarbamolTablet750 mg/1Oralbryant ranch prepack2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralKaiser Foundations Hospitals2015-06-04Not applicableUs
MethocarbamolTablet500 mg/1OralRemedy Repack2017-04-17Not applicableUs
MethocarbamolInjection, solution100 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2016-07-18Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RobaxinTablet500 mgOralPfizer Laboratories Div Pfizer Inc.1958-12-31Not applicableCanada
Robaxin 750Tablet750 mgOralPfizer Laboratories Div Pfizer Inc.1993-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A.S.A. With Methocarbamol Night-time Extra StrengthMethocarbamol (400 mg) + Acetylsalicylic acid (500 mg)TabletOralPharmetics (2011) Inc.Not applicableNot applicableCanada
Acetaminophen 325mg + Methocarbamol 400mg CapletsMethocarbamol (400 mg) + Acetaminophen (325 mg)TabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Acetaminophen 500mg + Methocarbamol 400mg Extra Strength CapletsMethocarbamol (400 mg) + Acetaminophen (500 mg)TabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Advil Back PainMethocarbamol (500 mg) + Ibuprofen (200 mg)TabletOralPfizer Laboratories Div Pfizer Inc.Not applicableNot applicableCanada
Analgesic and Muscle RelaxantMethocarbamol (500 mg) + Ibuprofen (400 mg)TabletOralPharmascience Inc2012-03-20Not applicableCanada
Analgesic and Muscle Relaxant CapletsMethocarbamol (500 mg) + Ibuprofen (200 mg)TabletOralTeva2009-11-18Not applicableCanada
Aspirin BackacheMethocarbamol (400 mg) + Acetylsalicylic acid (325 mg)TabletOralBayerNot applicableNot applicableCanada
Aspirin Night-timeMethocarbamol (400 mg) + Acetylsalicylic acid (500 mg)TabletOralBayer Inc Consumer Care2006-05-242010-08-05Canada
Axacet-C1/8Methocarbamol (400 mg) + Acetaminophen (325 mg) + Codeine phosphate (8 mg)TabletOralTechnilab Pharma Inc.Not applicableNot applicableCanada
Axisal-C1/8Methocarbamol (400 mg) + Acetylsalicylic acid (325 mg) + Codeine phosphate (8 mg)TabletOralTechnilab Pharma Inc.Not applicableNot applicableCanada
International/Other Brands
Bolaxin (Ying Yuan) / Carbaflex (Paill) / Delaxin / DoloVisan (Dr.Kade Pharmaceutische Fabrik) / Fubaxin (Grape King) / Lumirelax (Juvise) / Metocarbamol (AZ Pharma) / Mioflex (Labinco) / Miorel (Cheminter) / Musxan (Pharmasant) / Ortoton (Recordati) / Rebamol (Winston) / Robaxin / Robaxin-750 (Pfizer) / Robinax (Khandelwal) / Sinaxar (Armofar) / Taspan (Honten)
Categories
UNII
125OD7737X
CAS number
532-03-6
Weight
Average: 241.2405
Monoisotopic: 241.095022595
Chemical Formula
C11H15NO5
InChI Key
GNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
IUPAC Name
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
SMILES
COC1=CC=CC=C1OCC(O)COC(N)=O

Pharmacology

Indication

For use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.

Structured Indications
Pharmacodynamics

Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.

Mechanism of action

The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

TargetActionsOrganism
NCarbonic anhydrase 1
inhibitor
Human
Absorption

Rapid. Onset of action is about 30 minutes after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination

Small amounts of unchanged methocarbamol also are excreted in the urine.

Half life

1.14-1.24 hours

Clearance
  • 0.2 – 0.8 L/h/kg [healthy]
Toxicity

Symptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methocarbamol.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methocarbamol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Azaperone.Investigational, Vet Approved
AzelastineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methocarbamol.Approved
BarbitalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Bupivacaine.Approved, Investigational
BuprenorphineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methocarbamol.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methocarbamol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methocarbamol.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methocarbamol.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methocarbamol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.Approved
CocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methocarbamol.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methocarbamol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Methocarbamol.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methocarbamol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.Approved, Investigational
EthanolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methocarbamol.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Hexobarbital.Approved
HydrocodoneMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methocarbamol.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lormetazepam.Approved
LorpiprazoleThe therapeutic efficacy of Methocarbamol can be increased when used in combination with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Methocarbamol can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methaqualone.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.Approved
MethotrimeprazineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methylphenobarbital.Approved
MetyrosineMethocarbamol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
MirtazapineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methocarbamol.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methocarbamol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Opium.Approved, Illicit
OrphenadrineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.Approved
ParaldehydeMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
PerazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methocarbamol.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved
PramipexoleMethocarbamol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Methocarbamol can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Methocarbamol is combined with PSD502.Investigational
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methocarbamol.Approved, Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Romifidine.Vet Approved
RopiniroleMethocarbamol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ropivacaine.Approved
RotigotineMethocarbamol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methocarbamol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sultopride.Experimental
SuvorexantMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrodotoxin.Investigational
ThalidomideMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zolazepam.Vet Approved
ZolpidemMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methocarbamol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

General References
  1. Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed:2253675]
External Links
Human Metabolome Database
HMDB0014567
KEGG Drug
D00402
PubChem Compound
4107
PubChem Substance
46507761
ChemSpider
3964
ChEBI
77498
ChEMBL
CHEMBL1201117
PharmGKB
PA164749506
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Methocarbamol
ATC Codes
M03BA53 — Methocarbamol, combinations excl. psycholepticsM03BA03 — MethocarbamolM03BA73 — Methocarbamol, combinations with psycholeptics
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (121 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPain1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
4RecruitingTreatmentLow Back Pain (LBP)1
4RecruitingTreatmentRib Fractures / Wounds and Injuries1

Pharmacoeconomics

Manufacturers
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Ferndale laboratories inc
  • Forest laboratories inc
  • Able laboratories inc
  • American therapeutics inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Heather drug co inc
  • Hetero drugs ltd
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nylos trading co inc
  • Pharmeral inc
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Solco healthcare us llc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Tablicaps inc
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous1000 mg/10mL
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
TabletOral500 mg
Tablet, film coatedOral750 mg/1
TabletOral750 mg
LiquidIntramuscular; Intravenous100 mg
TabletOral
Prices
Unit descriptionCostUnit
Robaxin-750 750 mg tablet2.48USD tablet
Robaxin 100 mg/ml vial2.2USD ml
Robaxin-750 tablet1.99USD tablet
Robaxin 500 mg tablet1.68USD tablet
Methocarbamol powder0.95USD g
Methocarbamol 750 mg tablet0.49USD tablet
Methocarbamol 500 mg tablet0.38USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)93 °CPhysProp
water solubility7200 mg/L (at 25 °C)CHEM INSPECT TEST INST (1992)
logP0.61CHEM INSPECT TEST INST (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.21 mg/mLALOGPS
logP0.63ALOGPS
logP0.45ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.01 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.07 m3·mol-1ChemAxon
Polarizability24.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9638
Blood Brain Barrier+0.5747
Caco-2 permeable-0.6689
P-glycoprotein substrateNon-substrate0.6452
P-glycoprotein inhibitor INon-inhibitor0.9411
P-glycoprotein inhibitor IINon-inhibitor0.8887
Renal organic cation transporterNon-inhibitor0.9105
CYP450 2C9 substrateNon-substrate0.8431
CYP450 2D6 substrateNon-substrate0.7658
CYP450 3A4 substrateNon-substrate0.606
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9302
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9066
CYP450 3A4 inhibitorNon-inhibitor0.9338
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9542
Ames testNon AMES toxic0.5776
CarcinogenicityNon-carcinogens0.9406
BiodegradationNot ready biodegradable0.8358
Rat acute toxicity2.2930 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.984
hERG inhibition (predictor II)Non-inhibitor0.9411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-0900000000-97aeacf66e8410c23139
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-2900000000-df41a784aa756b8e064d

Taxonomy

Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Alkyl aryl ethers / Carbamate esters / Secondary alcohols / Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Carbamic acid ester / Carbonic acid derivative / Secondary alcohol / Ether / Alcohol
show 9 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carbamate ester, aromatic ether, secondary alcohol (CHEBI:77498)

Targets

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. [PubMed:1460006]

Drug created on June 13, 2005 07:24 / Updated on February 21, 2018 02:46